Archived explainer. For the current picture see today's KNSA page.
KINIKSA PHARMACEUTIC A (KNSA) is up +23.83% in the latest session. Our newswire has captured 7 stories on KNSA across 6 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
KNSA stock surged 23.83% to $78.67 in a dramatic session driven by strong Q2 2026 financial results and updated guidance for ARCALYST. The company reported a 55% year-over-year increase in ARCALYST net product revenue to $243.6 million and raised its 2026 sales guidance to $980, $995 million. Additionally, Kiniksa advanced its experimental drug KPL-387 into a pivotal Phase 3 trial for recurrent pericarditis, signaling progress in its pipeline.
Kiniksa Pharmaceuticals International reported second-quarter 2026 results that exceeded expectations. GAAP earnings per share came in at $0.30, beating estimates by $0.01, while revenue of $243.6 million surpassed forecasts by $17.14 million. The company cited strong performance from its flagship drug ARCALYST, which saw a 55% year-over-year increase in net product revenue. In addition to the financial update, Kiniksa announced the initiation of a pivotal Phase 3 trial for KPL-387, a development that underscores its strategic focus on expanding its therapeutic portfolio. The firm also filed a Form 8-K with the SEC on July 28, 2026, disclosing the results of operations and financial condition.
The stock opened at $65.00, a 2.3% gap up from the prior close, and reached a session high of $81.97 before settling at $78.48. Volume was 0.5 million shares, which is 0.7 times the 3-month daily average. The stock’s price action reflects a sharp reversal from its 52-week range of $26.27 to $67.53. The company has a market cap of $4.8 billion, a P/E ratio of 70.0, and trailing 12-month revenue growth of 56.7%. Analysts at Goldman Sachs and Wells Fargo have both raised their price targets to $75 and $74 respectively, maintaining their Buy and Overweight ratings.
Kiniksa has no upcoming earnings date in the immediate future, but investors will want to monitor the breadth of analyst coverage and any further developments from the KPL-387 Phase 3 trial.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Kiniksa reported strong Q2 2026 earnings, raised ARCALYST sales guidance to $980-$995 million, and advanced KPL-387 into a pivotal Phase 3 trial for recurrent pericarditis.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) reported second-quarter ARCALYST revenue of $243.6 million, up 55% from a year earlier and more than $29 million from the first quarter, as the company cited continued expansion in both new and repeat prescribers for the recurrent pericarditis trea
Kiniksa Pharmaceuticals raised its 2026 ARCALYST revenue guidance on the back of robust Q2 results and accelerating clinical progress. The company’s lead asset, ARCALYST, delivered 55% year-over-year net product revenue growth while next-in-line KPL-387 advanced into Phase 3—positioning Kiniksa as a key player in rare cardiovascular disease treatments.
Kiniksa (KNSA) Q2 earnings: GAAP EPS beat, revenue up 55% on ARCALYST.
Filed: 2026-07-28 AccNo: 0001730430-26-000031 Size: 368 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
– ARCALYST ¨ (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $980 - $995...
Kiniksa Pharma (KNSA) reports Q2 earnings July 28. See EPS/revenue forecasts, estimate revisions & past beats to prep for the stock—read now.
More on KNSA: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier KNSA move explainers: 2026-07-29 · 2026-07-28